1300031-62-2

Basic information

• Product Name: 3,5-dimethyl-4-[2-(methyloxy)-5-nitrophenyl]isoxazole
• Synonyms: 3,5-dimethyl-4-[2-(methyloxy)-5-nitrophenyl]isoxazole
• CAS NO: 1300031-62-2
• Molecular Weight: 248.238
• Mol File: 1300031-62-2.mol

Chemical Properties

• CAS DataBase Reference: 3,5-dimethyl-4-[2-(methyloxy)-5-nitrophenyl]isoxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-dimethyl-4-[2-(methyloxy)-5-nitrophenyl]isoxazole(1300031-62-2)
• EPA Substance Registry System: 3,5-dimethyl-4-[2-(methyloxy)-5-nitrophenyl]isoxazole(1300031-62-2)

Safety Data

• Hazardous Substances Data: 1300031-62-2(Hazardous Substances Data)

Upstream product

• 16114-47-9 3,5-dimethylisoxazole-4-boronic acid 
• 5399-03-1 2-iodo-1-methoxy-4-nitrobenzene 
• 10558-25-5 4-bromo-3,5-dimethyl-1,2-oxazole 

Downstream Products

• 1300031-49-5 I-BET151 
• 1300031-61-1 [3-(3,5-dimethyl-4-isoxazolyl)-4-(methyloxy)phenyl]amine 
• 1300031-60-0 1,3-diethyl 2-([[3-(3,5-dimethyl-1,2-oxazol-4-yl)-4-methoxyphenyl]amino]methylidene)propanedioate 
• 1300031-57-5 4-chloro-7-(3,5-dimethyl-4-isoxazolyl)-6-(methyloxy)-3-quinolinecarboxamide 
• 1300737-57-8 Ethyl 4-{[2-(1,1-di methylethyl)phenyl]amino}-7-(3,5-dimethyl-4-isoxazolyl)-6-(methoxy)-3-quinolinecarboxylate 
• 1300737-63-6 4-{[2-(1,1-dimethylethyl)phenyl]amino}-7-(3,5-dimethyl-4-isoxazolyl)-6-(methoxy)-3-quinolinecarboxylic acid hydrochloride 
• 1300737-69-2 7-(3,5-dimethyl-4-isoxazolyl)-6-(methyloxy)-4-{[(1R)-1-(2-pyridinyl)ethyl]amino}-3-quinolinecarboxamide 
• 1300737-60-3 C₂₅H₂₅N₃O₄ 
• 1300859-13-5 C₂₃H₂₁N₃O₄ 
• 1300859-10-2 C₂₆H₂₇N₃O₄ 
• 1372132-40-5 C₂₂H₁₉FN₄O₃ 
• 1373354-27-8 C₂₆H₂₈N₄O₃ 
• 1373354-29-0 C₂₈H₃₁N₅O₄ 
• 1373354-30-3 C₂₈H₂₃N₅O₄ 

Relevant articles and documents

METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE

The present disclosure relates to compounds and methods for modulating the expression of dmpk, and treating diseases and conditions in which dmpk plays an active role. The compound can be a transcription modulator molecule having a first terminus, a second terminus, and oligomeric backbone, wherein: a) the first terminus comprises a DNA-binding moiety capable of noncovalently binding to a nucleotide repeat sequence CAG or CTG; b) the second terminus comprises a protein-binding moiety binding to a regulatory molecule that modulates an expression of a gene comprising the nucleotide repeat sequence CAG or CTG; and c) the oligomeric backbone comprising a linker between the first terminus and the second terminus.

QUINOLINE DERIVATIVES AS BROMODOMAIN INHIBITORS

Provided is a novel quinoline derivative inhibiting the bromodomain and extra terminal domain (BET) proteins, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of a precancerous transformation or a cancer.

7-(3,5-Dimethyl-4-Isoxazolyl)-8-(Methyloxy)-1H-Imidazo[4,5-C]Quinoline Derivatives

Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.

4-(8-METHOXY-1-((1-METHOXYPROPAN-2-YL)-2-(TETRAHYDRO-2H-PYRAN-4-YL)-1 H-IMIDAZO[4,5-C]QUINOLIN-7-YL)-3,5-DIMETHYLISOXAZOLE AND ITS USE AS BROMODOMAIN INHIBITOR

Novel quinoline compounds of formula (I), pharmaceutical compositions containing such compounds and their use in therapy, as bromodomain inhibitors.

NOVEL COMPOUNDS

Novel quinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.

Imidazo [4, 5-C] Quinoline Derivatives As Bromodomain Inhibitors

Novel compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.

From ApoA1 upregulation to BET family bromodomain inhibition: Discovery of I-BET151

The discovery, synthesis and biological evaluation of a novel series of 7-isoxazoloquinolines is described. Several analogs are shown to increase ApoA1 expression within the nanomolar range in the human hepatic cell line HepG2.

IMIDAZO [4, 5-C] QUINOLINE DERIVATES AS BROMODOMAIN INHIBITORS

Novel compounds of Formula (I) and salts thereof, pharmaceutical compositions containing such compounds and their use in therapy.